ArticlePatient preference and adherence2019
Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment.
Article in Patient preference and adherence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Systematic Literature Review and Meta-Analysis of INSTI-Based Antiretroviral Therapy Single- Versus Multiple-Tablet Regimens for the Treatment of HIV.Advances in therapy · 2026Pooled it
- Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Antiretroviral therapy switch among Medicare beneficiaries with HIV.Journal of managed care & specialty pharmacy · 2026Article
- Antiretroviral therapy persistence among treatment-experienced people with HIV and mental health disorders and/or substance use disorders in the USA (2017-2024): a retrospective cohort study.Journal of comparative effectiveness research · 2026Article
- Factors associated with low-level viremia in people living with HIV: A 10-year retrospective study in South Korea.PloS one · 2026Article
- Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care.Infectious diseases and therapy · 2026Article
- Antiretroviral Treatment Switch Among Treatment-Experienced People with HIV.Journal of health economics and outcomes research · 2026Article
- Real-World Persistence in Adults with HIV and Mental Health or Substance Use Disorders After Restarting Antiretroviral Therapy in the United States.Advances in therapy · 2025Observational
- HIV drug resistance and its associated factors among patients during interruption of antiretroviral therapy in China.Frontiers in microbiology · 2025Article
- Acquired Human Immunodeficiency Virus Type 1 Drug Resistance in Rhode Island, USA, 2004-2021.The Journal of infectious diseases · 2024Article
- Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.Journal of managed care & specialty pharmacy · 2024Article
- Antiretroviral Treatment Gaps and Adherence Among People with HIV in the U.S. Medicare Program.AIDS and behavior · 2024Article
- Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.Immunity, inflammation and disease · 2023Article
- Factors Associated with Adherence to Treatment in Patients with HIV and Diabetes Mellitus.Journal of personalized medicine · 2023Article
- Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Real-World Adherence to Antiretroviral Therapy Among HIV-1 Patients Across the United States.Advances in therapy · 2021Observational
- Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.AIDS research and therapy · 2020Article
- Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide.Patient preference and adherence · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess adherence and persistence with first-line single-tablet regimen (STR) and multi-tablet regimen (MTR) antiretroviral therapy (ART) in newly treated HIV-1 patients.
methodsRetrospective analysis of longitudinal pharmacy claims among US patients initiating ART between 1/1/2016 and 5/31/2016 (index date was defined by first ART claim for STRs, and fill date for the last therapy in the regimen for MTRs). Adherence was assessed over a 12-month period and reported as the proportion of adherent or non-adherent (defined as ≤5-day and > a 5-day gap between successive fills, respectively) patients. Sensitivity analysis using ≤7-day and ≤14-day gap thresholds to define adherence was performed. Persistence was assessed as the number of days on therapy from index until treatment discontinuation (>90 day gap in therapy). Kaplan-Meier curves and Cox Proportional Hazard models were generated to evaluate discontinuation rates. Assessments were performed on STRs vs MTRs overall and by regimen.
resultsPatients initiating ART (STR: n=10,623; MTR: n=2504) had a mean age of 42.8 years; 76.0% were male. STR patients were >2 times more likely to be adherent over 12 months than MTR patients (24.9% vs 11.7%, respectively). Patients using EVG/COBI/FTC/TAF had greater adherence than those using other STRs. Among MTRs, patients were more adherent with FTC/TDF+DTG (15.1%) than other MTRs. Persistence was also greater with STRs, with MTR patients being 61% more likely to discontinue therapy. Persistence was best for FTC/TAF-based regimens. Predictors of treatment discontinuation included younger age, female gender, and Medicare or Medicaid insurance type.
conclusionPatients receiving STRs were significantly less likely to discontinue therapy and were more adherent with their regimens, providing further evidence of greater adherence and persistence with STRs versus MTRs. However, there was a large proportion of patients who interrupted or discontinued treatment. Further research examining treatment patterns beyond first line is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.